Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
EU Funding & Tenders Portal HORIZON-HLTH-2027-01-IND-01 · Horizon Europe (HORIZON)
| Funder | European Commission |
|---|---|
| Status | open |
| Opens | 29 Oct 2026 |
| Deadline | 17 Feb 2027 — 109 days |
| Action | HORIZON Research and Innovation Actions |
| Official page | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunit… |
| Last checked | 2026-10-31 06:01:29+00:00 |
The scope text was read and no clause in it rules a field out. That is not a guarantee — read the call before you commit to it.
You are reading one call. 1,050 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
This call page is free · no account · the report arrives by emailWhat this call is
| Instrument | HORIZON-RIA |
|---|---|
| Stages | single-stage |
| EU contribution | €6.0m to €8.0m per project |
| Projects expected | 4, sharing €24.5m |
From the Commission's own budget table for this call. Confirm against the topic page before you plan around it: these move when a work programme is amended.
Scope
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals. Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care. Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals. Scope: Cell-Free Protein Synthesis (CFPS) has been employed in fundamental biological research for decades, however, interest for the approach as a viable means for drug development and production has only emerged in recent years. The advantages that CFPS provides in terms of efficiency, simplicity, flexibility, cost- and time savings outweigh the hurdles that are still to be overcome for CFPS to become a routine manufacturing system for peptide- or protein-based biologicals. Currently, there are several CFPS systems used that are either based on prokaryotic or eukaryotic cell lysates (including mammalian) or fully synthetic systems consisting of all the molecular machinery necessary to create functional proteins. The choice of a specific lysate is dictated by the target protein and the end-use application. Proteins that require post-translational modification are generally produced using lysates of mammalian cells. Hence systems based on mammalian cells are of particular interest as they combine properties inherent to eukaryotic cells and their ability to produce human-like glycosylated proteins with the advantages of cell-free synthesis. These proteins include antibody fragments, antigens, virus-like particles, cytokines, enzymes, antimicrobial peptides and proteins containing non-natural amino acids. The benefits of CFPS are manifold, from ease of handling and scalability, on-demand launch of production, ability to rapidly switch products, simplified purification to facilitated standardisation and quality control. CFPS needs less energy resources, the manufacturing footprint is less complex and smaller than in cell cultivation and it enables production of proteins that have toxic effects on cells. In addition, CFPS has t…
What consortia for this call have looked like
4 projects
have been funded under this line
(HORIZON-HLTH-IND-01) in Horizon Europe and H2020. This is what they
were made of — not a recommendation, just what the Commission signed.
range 8–15
19 seen across all of them
across those projects
The mix of organisations
Who coordinated them
Coordinating an EU project is a demanding, specific job. These organisations have done it on this topic line before.
This is the shape, not the consortium. It says how many partners these projects had and what kinds of organisation were in them. It does not know whether your idea needs the same mix, who is available, who is already committed elsewhere, or how the work and the budget should be divided. Those are judgement calls on a specific proposal, and no amount of public data answers them.
Building the actual consortium — finding the partners, agreeing the roles, and writing it so it survives an evaluation — is what Scientific Network Management does. Free either way; the radar does not change if you never ask.
Get told when something changes
Most institutions find out about a call with three weeks left. We write when something opens, moves or closes that fits what you work on, with the deadline, the fit and the funder's own exclusion clauses quoted. Nothing in a quiet week. Free, and one click to leave.
Starting from the programme you are reading: Horizon Europe (HORIZON) — change it below if you like.
Leave the second box empty and you get whatever opened or changed recently, closing soonest. Fill it in and it ranks against your words instead: that is the difference between a list and a shortlist.
Scientific Network Management will send you the current list for these terms, and after that only what changes: a call that opens, a deadline that shifts, a clause that rules you out. Nothing is sent when nothing has moved. One click to stop, in every message.
One confirmation email and nothing else until you click it. No tracking pixels, no sharing, one click to unsubscribe.
Of every 100 Horizon Europe proposals
A funding strategy reads your institution's own published record against the calls that are open, and says in writing which are worth the year and which to decline, with the reason for each.
Scientific Network Management, the grant-writing practice behind this radar: 13 years of EU-funded research projects, and a founder who has served as Key Expert and Team Leader on two EU-funded technical assistance contracts establishing biotechnology centres in Türkiye.
SNM also does
No obligation, and nothing here is conditional on using us: searching the calls stays free and asks for nothing either way.